. 2016 Oct 26;8(6):10703–10713. doi: 10.18632/oncotarget.12926

Table 2. Efficacy results of 5 RCTs.

References	Arms	Sample Size	Patient Characteristic	Primary Endpoint	PFS						ORR (%)
References	Arms	Sample Size	Patient Characteristic	Primary Endpoint	Median (months)	HR	HR, 95% CI	Median (months)	HR	HR, 95% CI
GOG218	TC+PL	625	Newly diagnosed	PFS	10.3	0.770	0.681-0.870	39.3	0.885	0.750-1.040	NR
GOG218	TC+Bev+Bev(m)	623	Newly diagnosed	PFS	14.1	0.770	0.681-0.870	39.7	0.885	0.750-1.040	NR
ICON7	TC	764	Newly diagnosed	PFS	17.5	0.930	0.830-1.050	58.6	0.990	0.850-1.140	48.0
ICON7	TC+Bev+Bev(m)	764	Newly diagnosed	PFS	19.9	0.930	0.830-1.050	58.0	0.990	0.850-1.140	67.0
OCEANS	GC+PL	242	Recurrent	PFS	8.4	0.484	0.388-0.605	32.9	0.952	0.771-1.176	57.4
OCEANS	GC+Bev+Bev(m)	242	Recurrent	PFS	12.4	0.484	0.388-0.605	33.6	0.952	0.771-1.176	78.5
AURELIA	CT(PLD or PAC or TOP)	182	Recurrent	PFS	3.4	0.480	0.380-0.600	13.3	0.850	0.660-1.080	12.6
AURELIA	CT+Bev+Bev(m)	179	Recurrent	PFS	6.7	0.480	0.380-0.600	16.6	0.850	0.660-1.080	30.9
GOG213	TC	374	Recurrent	OS	10.4	0.614	0.522-0.722	37.3	0.827	0.683-1.005	NR
GOG213	TC+Bev+Bev(m)	374	Recurrent	OS	13.8	0.614	0.522-0.722	42.2	0.827	0.683-1.005	NR

TC, Paclitaxel+Carboplatin; GC, Gemcitabine+Carboplatin; PL, placebo; Bev(m), Bevacizumab (maintenance chemotherapy); CT, PLD or PAC or TOP; PLD, pegylated liposomal doxorubicin; PAC, weekly paclitaxel; TOP, topotecan; PFS, progression-free survival; OS, overall survival; ORR, objective response rate; CI, confidence interval; NR, not reported.